[Advanced medical therapy in patients with acute ischemic stroke].
Shima
Katsuji
K
shima@ndmc.ac.jp
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage; D000983:Antipyrine / Q000031:analogs & derivatives; D001120:Arginine / Q000031:analogs & derivatives; D001241:Aspirin / Q000008:administration & dosage*; D015195:Drug Design; D000077553:Edaravone; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D023281:Genomics; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D010875:Pipecolic Acids / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000628:therapy*; D013449:Sulfonamides; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; D010959:Tissue Plasminogen Activator; C031942:argatroban; D001241:Aspirin; D000077553:Edaravone; D000983:Antipyrine